Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · Real-Time Price · USD
1.050
-0.040 (-3.67%)
May 2, 2025, 11:30 AM EDT - Market open
Barinthus Biotherapeutics Employees
Barinthus Biotherapeutics had 105 employees as of December 31, 2024. The number of employees decreased by 25 or -19.23% compared to the previous year.
Employees
105
Change (1Y)
-25
Growth (1Y)
-19.23%
Revenue / Employee
$142,562
Profits / Employee
-$581,657
Market Cap
42.36M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 105 | -25 | -19.23% |
| Dec 31, 2023 | 130 | 23 | 21.50% |
| Dec 31, 2022 | 107 | 35 | 48.61% |
| Dec 31, 2021 | 72 | 24 | 50.00% |
| Dec 31, 2020 | 48 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
BRNS News
- 6 weeks ago - Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments - GlobeNewsWire
- 2 months ago - Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11 - Accesswire
- 4 months ago - Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update - GlobeNewsWire
- 5 months ago - Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer - GlobeNewsWire
- 6 months ago - Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion - GlobeNewsWire
- 6 months ago - Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B - GlobeNewsWire
- 6 months ago - Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results - GlobeNewsWire
- 11 months ago - Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections - GlobeNewsWire